###
中国临床研究英文版:2026,39(8):1204-1208,1214
本文二维码信息
码上扫一扫!
吲哚布芬治疗冠状动脉粥样硬化性心脏病合并肾功能不全的疗效
(河北中石油中心医院心血管内二科, 河北 廊坊 065000)
Efficacy of indobufen in the treatment of coronary atherosclerotic heart disease complicated with renal insufficiency
(Second Department of Cardiovascular Medicine,Hebei Petro China Central Hospital,Langfang,Hebei 065000,China)
摘要
本文已被:浏览 383次   下载 234次
Received:December 01, 2025   Published Online:August 25, 2026
中文摘要: 目的 比较吲哚布芬与常规抗血小板治疗对冠状动脉粥样硬化性心脏病(冠心病)合并肾功能不全的疗效及安全性,为此类患者抗血小板药物的合理选择提供参考。方法 选取2023 年5 月至2024 年5 月在河北中石油中心医院心内科就诊的150例冠心病合并肾功能不全患者作为研究对象,采用随机数字表法分为阿司匹林组、氯吡格雷组和吲哚布芬组,各50例。比较三组应用抗血小板药物治疗前、治疗后1周的血小板计数(PLT)、花生四烯酸(AA)和二磷酸腺苷(ADP)诱导的血小板聚集率(PAR),凝血功能指标[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT)、国际标准化比值(INR)]。随访1年,记录各组在6个月和1年时的主要不良心血管事件(MACEs)发生情况,以及1年内的不良反应与出血事件。结果 治疗后,三组PLT 与治疗前比较差异无统计学意义(P>0.05),而AA-PAR、ADP-PAR 均较治疗前显著降低(P<0.05)。但治疗后三组间PLT、AA-PAR 及ADP-PAR 比较差异均无统计学意义(P>0.05)。治疗后,三组APTT、PT、TT、INR 较治疗前差异无统计学意义(P>0.05),且组间比较差异亦无统计学意义(P>0.05)。随访6个月及1年后,三组心绞痛、急性心肌梗死、心源性死亡、支架内血栓等MACEs 发生率比较差异无统计学意义(P>0.05)。阿司匹林组、氯吡格雷组和吲哚布芬组的MACEs 总发生率在随访6 个月时分别为10.00%(5/50)、8.00%(4/50)和8.00%(4/50),随访1年时分别为20.00%(10/50)、14.00%(7/50)和10.00%(5/50),三组比较差异均无统计学意义(6个月:χ2=0.240,P=0.887;1年:χ2=1.872,P=0.392)。随访1年,吲哚布芬组消化道症状不良反应发生率、出血事件总发生率均低于阿司匹林组(P<0.05),与氯吡格雷组比较差异无统计学意义(P>0.05)。结论 在冠心病合并肾功能不全患者的长期单联抗血小板治疗中,吲哚布芬与阿司匹林、氯吡格雷的抗血小板疗效相当,均能有效抑制血小板聚集且对凝血功能无明显影响,三组MACEs 发生率相近,其中吲哚布芬在减少消化道症状及出血事件方面优于阿司匹林,可作为此类患者尤其是阿司匹林不耐受或出血高风险人群抗血小板治疗的优选方案之一。
Abstract:Objective To compare the efficacy and safety of indobufen and conventional antiplatelet regimens in the treatment of coronary atherosclerotic heart disease (CHD)complicated with renal insufficiency,and to provide a reference for the rational selection of antiplatelet drugs in clinical practice. Methods A total of 150 patients with CHD complicated with renal insufficiency who were treated in the Department of Cardiology of Hebei Petro China Central Hospital from May 2023 to May 2024 were selected and randomly divided into aspirin group,clopidogrel group and indobufen group by the random number table method,with 50 cases in each group. The platelet count(PLT),platelet aggregation rate(PAR)induced by arachidonic acid(AA)and adenosine diphosphate(ADP),and parameters of coagulation function[activated partial thromboplastin time(APTT),prothrombin time(PT),thrombin time(TT),international normalized ratio(INR)]were compared among the three groups before antiplatelet therapy and 1 week after treatment. Follow-up was conducted for 1 year, and the occurrence of major adverse cardiovascular events(MACEs)in each group at 6 months and 1 year, as well as adverse reactions and bleeding events occurring within 1 year were recoded. Results After treatment,there was no significant change in PLT in the three groups compared with that before treatment(P>0.05),and AA-PAR and ADP-PAR in the three groups were significantly lower than those before treatment(P<0.05);there was no significant difference in PLT,AA-PAR and ADP-PAR among the three groups(P>0.05). After treatment,APTT,PT,TT and INR in the three groups had no significant changes compared with those before treatment(P>0.05),and there was no significant difference among the three groups(P>0.05). At 6 months and 1 year of follow-up,there was no statistically significant difference in the incidence of MACEs,including angina pectoris,acute myocardial infarction,cardiac death,and in-stent thrombosis,among the three groups(P>0.05). The total MACEs incidence rates in the aspirin group,clopidogrel group,and indobufen group at 6 months were 10.00%(5/50),8.00%(4/50)and 8.00%(4/50),respectively;and at 1 year,they were 20.00%(10/50),14.00%(7/50)and 10.00%(5/50),respectively. There was no statistically significant difference among the three groups(6 months:χ2=0.240,P=0.887;1 year:χ2=1.872,P=0.392).At the 1-year follow-up,the incidence of gastrointestinal symptoms and the total bleeding event incidence in the indobufen group were lower than those in the aspirin group(P<0.05),and there was no significant difference compared with that of the clopidogrel group (P>0.05). Conclusion In the long - term single antiplatelet therapy for patients with CHD complicated with renal insufficiency,indobufen has comparable antiplatelet efficacy to both aspirin and clopidogrel. All three drugs can effectively inhibit platelet aggregation,exert no significant effect on coagulation function,and show comparable MACEs incidence during follow-up. Among them,indobufen is superior to aspirin in reducing gastrointestinal symptoms and bleeding events,and can be used as one of the preferred antiplatelet therapy options for such patients,especially those who are intolerant to aspirin or at high risk of bleeding.
文章编号:     中图分类号:R541.4 R692    文献标志码:A
基金项目:廊坊市科技支撑计划项目(2023013035)
引用文本:


Scan with WeChat

Scan with WeChat